Search Medical Condition
Please enter condition
Please choose location

Uniontown, Ohio Clinical Trials

A listing of Uniontown, Ohio clinical trials actively recruiting patient volunteers.

RESULTS

Found (242) clinical trials

Observational Registry of H.P. Acthar Gel for Multiple Sclerosis Relapse

This observational study aims to characterize the patient population and describe multiple sclerosis exacerbation recovery, treatment patterns and safety outcomes in patients with multiple sclerosis experiencing exacerbations treated with H.P. Acthar Gel (Acthar Gel) in standard practice in the United States.

Phase N/A

0.0 miles

Learn More »

Memory Gel and Shape Combined Cohort

The post-approval study will include 2518 women undergoing breast augmentation or reconstruction with MemoryShape or MemoryGel Breast Implants. Four cohorts will be included: primary augmentation, revision-augmentation, primary reconstruction, and revision-reconstruction. For the purpose of assessing rheumatological and neurological signs and symptoms, a control group of 300 women will be selected ...

Phase N/A

0.0 miles

Learn More »

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

This is a randomized, double-blind, double-dummy, active comparator-controlled, parallel-group, multicenter study with variable treatment duration in approximately 900 patients with relapsing MS. The maximal treatment duration in the study for an individual patient will be 2.5 years. Eligible patients will be randomized to receive either experimental ofatumumab subcutaneous (sc) injections ...

Phase

0.0 miles

Learn More »

Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)

The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone compared with placebo in pediatric outpatients (7-17 years of age) with major depressive disorder.

Phase

7.85 miles

Learn More »

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

This is a Phase 2, multicenter, open label, non-randomized study to evaluate the safety and efficacy of a 30-minute infusion of 70 mg/m2 of carfilzomib among MM patients who are currently showing progressive disease (PD) and had failed their last treatment with twice weekly 27mg/m2 of carfilzomib alone or as ...

Phase

7.85 miles

Learn More »

The purpose of this Study is to find out if the study drug ruxolitinib (“Study Drug” or ruxolitinib) is safe and effective compared to anagrelide hydrochloride (also known as Agrylin® or anagrelide), in people who have Essential Thrombocythemia (ET) and are resistant to or intolerant of Hydroxyurea. 

Phase

7.85 miles

Learn More »

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative HR Positive MBC (CONTESSA)

This is a multinational, multicenter, randomized, open-label, parallel group Phase 3 study. The primary objective is to compare the efficacy of tesetaxel plus a reduced dose of capecitabine versus the approved dose of capecitabine alone based on PFS, as assessed by an Independent Radiologic Review Committee (IRC), in patients with ...

Phase

7.85 miles

Learn More »

Study of AM0010 With Nivolumab Compared to Nivolumab Alone Second-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer

This is an open-label, multi-center, randomized, Phase 2 study designed to compare the efficacy and safety of AM0010 in combination with Nivolumab versus Nivolumab alone in patients with stage IV / metastatic wild type Non-Small Cell Lung Cancer and tumors with low tumor expression of PD-L1 (0-49%)

Phase

7.85 miles

Learn More »

A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)

This is a multicenter, open-label study in participants with triple negative breast cancer (TNBC) to study the safety, tolerability, pharmacokinetics and preliminary efficacy of SC-005. This study consists of 2 parts: Part A (dose regimen finding) followed by Part B (dose expansion).

Phase

7.85 miles

Learn More »

KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD

The study will consist of a Screening Period, a Dose Optimization Phase, and a Treatment Phase and a Follow-Up Visit, as follows: Screening Period: Subjects will undergo a screening period up to 30 days prior to entering the Dose Optimization Phase. Dose Optimization Phase: During the Dose Optimization Phase, subjects ...

Phase

7.85 miles

Learn More »